Enhancing immunotherapy efficacy in colorectal cancer: targeting the FGR-AKT-SP1-DKK1 axis with DCC-2036 (Rebastinib)

Enhancing immunotherapy efficacy in colorectal cancer: targeting the FGR-AKT-SP1-DKK1 axis with DCC-2036 (Rebastinib)

Abstract This research demonstrates that DCC-2036 (Rebastinib), a potent third-generation tyrosine kinase inhibitor (TKI), effectively suppresses tumor growth in colorectal cancer (CRC) models with functional immune systems. The findings underscore the capacity of DCC-2036 to enhance both the activa...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiguang Chen, Qiting Zeng, Liyang Yin, Bingru Yan, Chen Wu, Jianbo Feng, Ying Wu, Jun He, Wenjun Ding, Jing Zhong, Yingying Shen, Xuyu Zu
Format: Article
Language:English
Published: Nature Publishing Group 2025-01-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-024-07263-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41419-024-07263-8

Similar Items